A study of VRDN-003 in participants with chronic thyroid eye disease (TED) (H-56151)
Description
Content
A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
To determine the efficacy, safety, and tolerability of subcutaneously administered VRDN-003 (VRDN-003 SC) using Q4W or Q8W regimen compared to placebo in participants with chronic TED.
Approximately 126 participants with chronic TED will be randomized worldwide.
To learn more about the REVEAL 2 study, visit clinicaltrials.gov/study/NCT06625398 and contact the study team below.
Contact
Phone 1: 713–798–7692
IRB: H-56151
Status:
Active
Created:
